This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Discussing the Phase 3 DAYBREAK study of Zeposia (ozanimod), an oral medication that has been FDA approved for treatment of Multiple Sclerosis.
Ticker(s): BMYWho's the expert?
Institution: Northwell Health
- Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
- Treats >75 patients with AD.
- Has NOT prescribed Aduhelm (in July 2021 she was planning to start selecting patients to try it on).
- Familiar with the Clarity AD trial
Interview Goalthe Phase 3 DAYBREAK study of Zeposia (ozanimod), an oral medication that has been FDA approved for treatment of Multiple Sclerosis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
